Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AK112 with or without VG2025 in colorectal cancer liver metastases
CTR20260440Phase 2Active
- Sponsor
- CTTQ-Akeso
- Start
- May 2026
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of ivonescimab in colorectal cancer (CRC), sponsored by CTTQ-Akeso. Started May 2026; status: active.
02
Drugs
ivonescimab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on CTR20260440.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20260440.